Toxic proteins application in cancer therapy.

Abstract

Ribosome inactivating proteins (RIPs) as family of anti-cancer drugs recently received much attention due to their interesting anti-cancer mechanism. In spite of small drugs, RIPs use the large-size effect (LSE) to prevent the efflux process governed by drug resistance transporters (DRTs) which prevents inside of the cells against drug transfection. There are many clinical translation obstacles that severely restrict their applications especially their delivery approach to the tumor cells. As the main goal of this review, we will focus on trichosanthin (TCS) and gelonin (Gel) and other types, especially scorpion venom-derived RIPs to clarify that they are struggling with what types of bio-barriers and these challenges could be solved in cancer therapy science. Then, we will try to highlight recent state-of-the-arts in delivery of RIPs for cancer therapy.

• Authors: Zahra Setayesh-Mehr, Mahdiye Poorsargol
• Journal: Molecular biology reports (Mol Biol Rep) Vol. 48 Issue 4 Pg. 3827-3840 (Apr 2021) ISSN: 1573-4978 [Electronic] Netherlands
• PMID: 33895972 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents, Phytogenic
• Ribosome Inactivating Proteins, Type 1
• Scorpion Venoms
• Sodium Channel Blockers
• Trichosanthin
• GEL protein, Gelonium multiflorum

Topics

• Animals
• Antineoplastic Agents, Phytogenic (therapeutic use, toxicity)
• Humans
• Neoplasms (drug therapy)
• Ribosome Inactivating Proteins, Type 1 (therapeutic use, toxicity)
• Scorpion Venoms (therapeutic use, toxicity)
• Sodium Channel Blockers (therapeutic use, toxicity)
• Trichosanthin (therapeutic use, toxicity)